Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancerItsuto Hamano, Chikara Οhyama, Jiro Shimoda et al.|World Journal of Urology|2019Cited by 40
Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration‐sensitive prostate cancer: A multicenter retrospective studyShingo Hatakeyama, Chikara Οhyama, Shintaro Narita et al.|International Journal of Urology|2020Cited by 28
Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.Itsuto Hamano, Chikara Οhyama, Shingo Hatakeyama et al.|Journal of Clinical Oncology|2020Cited by 0
MP37-10 ASSOCIATION OF TUMOR BURDEN WITH THE ELIGIBILITY OF UPFRONT THERAPY IN PATIENTS WITH CASTRATION NAIVE PROSTATE CANCER: A MULTICENTER RETROSPECTIVE STUDYToshikazu Tanaka, Chikara Οhyama, Hiromichi Iwamura et al.|The Journal of Urology|2020Cited by 0
MP09-19 PSA KINETICS IN INITIAL ANDROGEN DEPRIVATION THERAPY IS A PROGNOSTIC FACTOR IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCERItsuto Hamano, Chikara Οhyama, Shingo Hatakeyama et al.|The Journal of Urology|2020Cited by 0